Efficacy and Safety of Terbinafine versus Itraconazole in the treatment of Recurrent Tinea Corporis and Tinea Cruris: A Prospective, Randomized, Comparative study - NI

Pt BD Sharma PGIMS Rohtak0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年8月21日

试验速览

暂无简介。

•1. Patients 18-65 years of age of either gender
•2. Patient who has recurrence of lesions of tinea corporis and tinea cruris in less than 6 weeks after completion of treatment
•3. Patient willing to provide written informed consent
•4. Patients willing to come for regular follow-up

•1. Patient suffering from tinea infections other than tinea corporis and tinea cruris
•2. Patients with a history of intolerance or hypersensitivity to the study drugs
•3. Patients who have a serious concomitant illness that can prevent the completion of the study
•4. Patients with contact dermatitis, atopic dermatitis, psoriasis, or any other skin disease
•5. All pregnant and breastfeeding females
•6. Patients with hepatic, renal, or cardiac disease
•7. Patients on drugs that are contraindicated for use with itraconazole, which include pimozide, dofetilide, quinidine, oral midazolam, triazolam, nisoldipine, felodipine, dihydroergotamine, ergotamine, ergometrine, methylergometrine, cisapride, lovastatin, simvastatin, levacetylmethadol, and methadone.
•8. Patients on drugs that are contraindicated for use with terbinafine, which include tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B

发起方

Pt BD Sharma PGIMS Rohtak